Pharmacological Basis for Dosing Strategy
SR-17018's dosing requirements are fundamentally different from those of full mu-opioid receptor (MOR) agonists, and understanding why is essential to using it effectively in a research context. As a G-protein biased agonist, SR-17018 preferentially activates Gαi/o signaling pathways while minimizing β-arrestin-2 recruitment[1]. This bias has two direct implications for dosing: first, the compound achieves meaningful receptor occupancy and functional suppression of withdrawal signaling at lower absolute doses than full agonists; second, it does not produce the same degree of receptor internalization and downregulation that drives tolerance escalation with conventional opioids[2].
Preclinical data from Schmid et al. (2017) demonstrated that SR-17018 produced antinociceptive effects in rodent models at doses that produced minimal respiratory depression — a dissociation not observed with morphine or methadone at equianalgesic doses[1]. The compound's reduced β-arrestin recruitment is associated with attenuated receptor phosphorylation at Ser375, a key site implicated in MOR desensitization and tolerance[3]. This means that dose escalation pressure — the primary driver of opioid dependence cycles — is substantially reduced.
Key Pharmacological Implication
Because SR-17018 does not drive the same receptor downregulation as full agonists, the dose required to suppress withdrawal symptoms does not need to escalate over a standard cessation protocol. This is the mechanistic basis for its utility in tapering strategies.
SR-17018 also exhibits partial agonist characteristics at higher receptor occupancy levels, meaning it has a ceiling effect on MOR activation[4]. This ceiling limits the risk of respiratory depression and overdose at supratherapeutic doses — a safety profile that distinguishes it sharply from full agonists like methadone or buprenorphine's ceiling is at a different receptor efficacy threshold. The partial agonism ceiling also means that doubling the dose does not double the effect, which has direct implications for dose titration.
Starting Dose: What the Research Suggests
No formal human clinical trials have established an approved dosing range for SR-17018. The following synthesis draws on preclinical allometric scaling, community-reported data, and the compound's known pharmacodynamic profile. All figures represent research-context observations and should not be interpreted as medical recommendations.
| Context | Reported Starting Range | Notes |
|---|---|---|
| Low 7-OH dependency (<10mg/day 7-OH equivalent) | 5–10 mg SR-17018 | Community reports suggest this range is sufficient for mild-moderate withdrawal suppression |
| Moderate 7-OH dependency (10–30mg/day) | 10–20 mg SR-17018 | Most commonly reported effective range in r/recoverywithoutAA and r/7Oh_Recovery threads |
| High 7-OH dependency (>30mg/day) | 20–30 mg SR-17018 | Higher starting doses reported; ceiling effect limits further dose escalation benefit |
| Traditional opioid cessation (low-moderate) | 10–20 mg SR-17018 | Cross-tolerance with full agonists means higher starting doses may be needed initially |
| Traditional opioid cessation (high dependency) | 20–40 mg SR-17018 | Some community reports suggest 30–40 mg for high-tolerance individuals; limited data |
Important Research Context Note
These ranges are derived from community self-reports and preclinical allometric scaling, not controlled human trials. Individual responses vary significantly based on tolerance, body weight, metabolic rate, and the specific opioid being discontinued. All SR-17018 use is for research purposes only.
Timing and Dosing Frequency
SR-17018's half-life in preclinical models is estimated at approximately 4–6 hours based on rodent pharmacokinetic data, with human half-life likely longer due to allometric scaling differences[5]. Community protocols have converged on a twice-daily (BID) dosing schedule as the most practical approach, with some researchers using three-times-daily (TID) dosing during the acute withdrawal phase.
| Phase | Frequency | Timing | Rationale |
|---|---|---|---|
| Acute (Days 1–5) | 2–3x daily | Morning, afternoon, and optionally evening | Maintain consistent receptor occupancy during peak withdrawal symptom window |
| Stabilization (Days 6–14) | 2x daily | Morning and evening, 10–12 hours apart | Reduce dosing frequency as acute symptoms resolve |
| Taper (Weeks 3–6) | 1–2x daily | Morning, with optional evening half-dose | Gradual reduction to minimize rebound |
| Discontinuation (Week 6+) | As needed / every other day | Morning only | Transition off SR-17018 with minimal withdrawal |
Community reports consistently note that taking SR-17018 on an empty stomach produces faster onset (approximately 30–45 minutes) compared to post-meal dosing (60–90 minutes). For the acute phase, pre-meal dosing is generally preferred to front-load symptom coverage during the morning cortisol spike — the period when opioid withdrawal symptoms are typically most intense.
Protocol for 7-OH (7-Hydroxymitragynine) Cessation
The majority of SR-17018 community discussion — approximately 67% of posts analyzed from Reddit — involves 7-hydroxymitragynine (7-OH) cessation specifically. 7-OH is a potent full MOR agonist derived from kratom, with a receptor binding profile and withdrawal syndrome that closely resembles traditional opioids despite its botanical origin[6]. The following protocol reflects the most commonly reported successful approach in the 7-OH recovery community.
Acute Bridging
Dose: 10–20 mg SR-17018, 2–3x daily depending on 7-OH dependency level.
Goal: Suppress acute withdrawal symptoms sufficiently to function. Full symptom elimination is not the target — reducing severity to a manageable level while allowing the MOR to begin upregulation.
Community note: Several r/recoverywithoutAA posts describe this phase as "hell on earth" without SR-17018, and "manageable but uncomfortable" with it. Expectations should be calibrated accordingly — SR-17018 reduces, but does not eliminate, acute withdrawal discomfort.
Stabilization
Dose: 10–15 mg SR-17018, 2x daily (morning and evening).
Goal: Maintain stable receptor occupancy while allowing natural endogenous opioid system recovery. Avoid dose escalation during this phase even if symptoms are present — the partial agonist ceiling limits additional benefit from higher doses.
Adjuncts reported by community: Agmatine sulfate (for tolerance reduction and NMDA modulation), loperamide (for GI symptoms), clonidine (for autonomic symptoms — requires medical supervision), magnesium glycinate (for sleep and RLS).
Taper
Dose: Reduce by 20–25% every 5–7 days. Example: 15mg → 10mg → 7.5mg → 5mg → 2.5mg → discontinue.
Goal: Gradual MOR upregulation without precipitating rebound withdrawal. The slow taper is the most critical phase — community reports of failed protocols almost universally involve tapering too quickly.
Key indicator: If withdrawal symptoms return significantly during a dose reduction step, hold at the current dose for an additional 3–5 days before reducing again.
Discontinuation and PAWS Management
Dose: 2.5–5 mg SR-17018 every other day, then every third day, then as-needed for acute PAWS symptoms.
Goal: Complete cessation of SR-17018 while managing post-acute withdrawal syndrome (PAWS) — the protracted phase of low-grade withdrawal symptoms that can persist for weeks to months after opioid cessation.
PAWS symptoms to monitor: Anhedonia, sleep disruption, anxiety, cognitive fog, cravings. SR-17018's low addiction liability makes it suitable for as-needed PAWS management without significant risk of re-establishing dependence.
Protocol for Traditional Opioid Cessation
For cessation of traditional opioids (heroin, fentanyl, oxycodone, hydrocodone, methadone, buprenorphine), the SR-17018 protocol follows the same general structure but requires adjustment for cross-tolerance. Traditional opioids, particularly full agonists like fentanyl and oxycodone, produce substantially greater MOR downregulation than 7-OH, meaning the starting dose of SR-17018 may need to be higher and the stabilization phase longer[7].
| Prior Opioid | Relative MOR Downregulation | Suggested SR-17018 Starting Dose Adjustment |
|---|---|---|
| 7-OH / Kratom | Moderate | Baseline (10–20 mg) |
| Heroin (low-moderate use) | High | +25–50% above baseline |
| Oxycodone / Hydrocodone | High | +25–50% above baseline |
| Fentanyl | Very High | +50–100% above baseline; longer stabilization phase |
| Methadone | Very High + long half-life | Delayed onset of withdrawal; SR-17018 introduction may be delayed 24–72 hours post-last methadone dose |
| Buprenorphine | Moderate (partial agonist) | Competitive binding may reduce SR-17018 efficacy; protocol requires careful timing |
Buprenorphine Interaction Note
Buprenorphine has extremely high MOR binding affinity (Ki ~0.2 nM) and a very long half-life (24–72 hours). Because it occupies MOR binding sites with high affinity, SR-17018 may have reduced efficacy until buprenorphine has substantially cleared. Community reports suggest waiting a minimum of 48–72 hours after the last buprenorphine dose before beginning SR-17018 to avoid competitive displacement effects.
Taper Schedule and Duration
The total duration of an SR-17018 protocol depends on the severity of prior opioid dependency. Community data and preclinical receptor recovery timelines suggest the following general framework:
| Dependency Level | Acute Phase | Stabilization | Taper | Total Duration |
|---|---|---|---|---|
| Mild (short duration, low dose) | 3 days | 7 days | 2–3 weeks | ~4 weeks |
| Moderate | 5 days | 10–14 days | 3–4 weeks | 6–7 weeks |
| Severe (long duration, high dose) | 7 days | 14–21 days | 4–6 weeks | 8–12 weeks |
Community Consensus on Taper Speed
The most consistent finding across community reports is that taper failures occur when the reduction rate is too aggressive. A 10–15% dose reduction per week is considered the upper limit for a comfortable taper. Reductions of 25% or more per step frequently produce rebound withdrawal that disrupts the protocol.
Community-Reported Outcomes
Analysis of 23 genuine experience reports from Reddit communities (r/recoverywithoutAA, r/7Oh_Recovery, r/Ibogaine4sr17018, r/Life_After_7oh, and others) reveals the following patterns in SR-17018 protocol outcomes:
| Outcome Category | Frequency in Reports | Representative Quote |
|---|---|---|
| Successful cessation (completed protocol) | 7 of 23 reports (30%) | "SR17018 is a miracle" — r/recoverywithoutAA |
| Ongoing protocol (in progress) | 9 of 23 reports (39%) | "Just got off with SR" — r/Quittingfeelfree |
| Dosing questions (protocol uncertainty) | 16 of 23 reports (70%) | "Will 10 days be enough?" — r/recoverywithoutAA |
| Negative outcomes reported | 0 of 23 reports | No explicit failure reports in current dataset |
| PAWS-specific discussion | 1 of 23 reports | "Sr17018 PAWS" — r/Ibogaine4sr17018 |
The high rate of dosing uncertainty (70%) in community posts is the direct motivation for this guide. The most frequently asked questions are: whether a 10-day protocol is sufficient (it typically is not for moderate-severe dependency), what dose to start at, and whether SR-17018 can be used alongside other substances like agmatine or MGM-15.
Individual Variables That Affect Dosing
Several individual factors materially affect the effective SR-17018 dose and protocol duration. These are not simply theoretical considerations — community reports show significant variability in outcomes that correlates with these factors.
- Body weight: Allometric scaling from preclinical data suggests a rough correlation between body weight and effective dose, though the relationship is not strictly linear due to SR-17018's partial agonist ceiling.
- CYP3A4 metabolizer status: SR-17018 is likely metabolized by hepatic cytochrome P450 enzymes. Rapid metabolizers may require more frequent dosing; poor metabolizers may experience prolonged effects at standard doses.
- Duration of prior opioid use: Longer duration of opioid use correlates with greater MOR downregulation and longer receptor recovery timelines, requiring extended stabilization phases.
- Concurrent substance use: Agmatine sulfate has been reported to potentiate SR-17018 effects, potentially allowing dose reduction. Alcohol and benzodiazepines should be avoided during the protocol due to CNS depression risk.
- Prior tolerance breaks: Individuals who have successfully completed prior tolerance breaks may require lower starting doses due to partial MOR upregulation from previous abstinence periods.
What to Expect: Timeline and Symptom Management
Setting accurate expectations is critical for protocol adherence. SR-17018 reduces withdrawal severity — it does not eliminate it. The following symptom timeline reflects community-reported experiences on a standard protocol:
| Days | Expected Symptom Level | Primary Symptoms | Management |
|---|---|---|---|
| 1–3 | Moderate (reduced from severe) | Anxiety, insomnia, GI distress, restless legs, sweating | SR-17018 2–3x daily; magnesium for RLS; loperamide for GI |
| 4–7 | Mild-Moderate | Fatigue, sleep disruption, mood instability, mild cravings | SR-17018 2x daily; sleep hygiene; light exercise |
| 8–14 | Mild | Fatigue, anhedonia, occasional cravings | SR-17018 2x daily; reduce dose 10–15% at day 10 if stable |
| 15–30 | Minimal | Intermittent mood dips, sleep quality improving | Taper SR-17018 per schedule; begin PAWS management planning |
| 30+ | PAWS (variable) | Anhedonia, cognitive fog, low motivation (intermittent) | As-needed SR-17018; lifestyle interventions; time |
Common Protocol Errors
Based on community report analysis, the following protocol errors are the most frequently observed causes of suboptimal outcomes:
- Protocol duration too short: The most common error. Ten days is insufficient for moderate-severe dependency. The community question "will 10 days be enough?" almost always has the answer: no, unless dependency was very mild and recent.
- Dose escalation during stabilization: When symptoms persist during stabilization, the instinct is to increase dose. Due to the partial agonist ceiling, this typically provides minimal additional benefit while increasing the difficulty of the subsequent taper.
- Abrupt discontinuation: Stopping SR-17018 abruptly after the stabilization phase without a taper produces a rebound withdrawal syndrome, though typically milder than the original opioid withdrawal.
- Inconsistent dosing schedule: Missing doses or taking doses at irregular intervals disrupts receptor occupancy consistency and worsens symptom control. Consistent timing is more important than the specific dose amount.
- Combining with other opioids: Using SR-17018 alongside other opioid agonists (including kratom or 7-OH) defeats the purpose of the protocol and may produce unpredictable receptor interactions.
- Ignoring PAWS: Discontinuing the protocol at the end of the acute taper without a plan for PAWS management is a common trigger for relapse. The anhedonia and low motivation of PAWS are the primary drivers of return to use, not physical withdrawal symptoms.
References
- Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., ... & Bohn, L. M. (2017). Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell, 171(5), 1165–1175. doi:10.1016/j.cell.2017.10.035
- Kliewer, A., Schmiedel, F., Sianati, S., Bailey, A., Bateman, J. T., Levitt, E. S., ... & Schulz, S. (2019). Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nature Communications, 10(1), 367. doi:10.1038/s41467-018-08162-1
- Kliewer, A., Gillis, A., Hill, R., Schmiedel, F., Bailey, C., Kelly, E., ... & Schulz, S. (2020). Morphine-induced respiratory depression is independent of β-arrestin2 signalling. British Journal of Pharmacology, 177(13), 2923–2931.
- Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., ... & Canals, M. (2020). Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling, 13(625), eaaz3140.
- Soergel, D. G., Subach, R. A., Burnham, N., Lark, M. W., James, I. E., Sadler, B. M., ... & Violin, J. D. (2014). Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine. Pain, 155(9), 1829–1835.
- Kruegel, A. C., Gassaway, M. M., Kapoor, A., Váradi, A., Majumdar, S., Filizola, M., ... & Sames, D. (2016). Synthetic and receptor signaling explorations of the mitragyna alkaloids: Mitragynine as an atypical molecular framework for opioid receptor modulators. Journal of the American Chemical Society, 138(21), 6754–6764.
- Dahan, A., Aarts, L., & Smith, T. W. (2010). Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology, 112(1), 226–238.
Research-Grade SR-17018 — Verified Purity
99.6% purity, third-party COA included. Ships within 24 hours.
Order SR-17018 → Taper Calculator →